Combined Biomimetic MOF-RVG15 Nanoformulation Efficient Over BBB for Effective Anti-Glioblastoma in Mice Model [Corrigendum]

Abstract

Wu H, Liu Y, Chen L, et al. Int J Nanomedicine. 2022;17:6377–6398. The authors have advised there is an error in Figure 8A on page 6392. Due to an error that occurred inadvertently at the time of figure assembly, the images of the fluorescence intensity of RVG15-PEG@IR-820@ZIF-8 at the 8 h are incorrect. The correct Figure 8 is as follows Figure 8 Continued. Figure 8 Biodistribution of free IR-820, IR-820@ZIF-8, and RVG15-PEG@IR-820@ZIF-8 in vivo. (A) In vivo fluorescence imaging of orthotopic glioma-bearing mice treated with free IR-820, IR-820@ZIF-8, and RVG15-PEG@IR-820@ZIF-8 at 1, 4, 8, and 24 h. (B) Ex vivo fluorescence images of the excised brains and major organs at 24 h after injection. (C) Quantitative region-of-interest analysis of (B). Means ± SD, n = 3; *P < 0.05. . The authors wish to apologize for this error and advise it does not affect the interpretation of the data and the conclusion of the study.

Keywords

• glioblastoma
• blood–brain barrier
• rvg15
• biomimetic nanoparticle
• zeolitic imidazolate frameworks-8(zif-8)